ZV05  (Synonyms: ZV0501 Antibody)

ZV05 (ZV0501 Antibody) is an anti-5T4 monoclonal antibody with an EC₅₀ of 4.3 ng/mL against h5T4. ZV05 does not induce apoptosis or interfere with cell cycle progression. ZV05 accumulates specifically in 5T4-positive tumor xenografts. ZV05 can serve as the antibody component of antibody-active molecule conjugates (ADCs) to bind the 5T4 glycoprotein, thereby enabling targeted delivery of toxins. ZV05 is used in studies of 5T4-positive cancers, including triple-negative breast cancer^[1][2].

Human

ZV05 (0.051-3000 ng/mL; 2 h) binds to the purified extracellular domain protein of h5T4, with an EC₅₀ of 4.3 ng/mL^[1].
ZV05 (0.01-10 μg/mL; 30 min on ice) specifically binds to the 5T4-positive cancer cell lines MDA-MB-468, DU 145 and BxPC-3, but does not bind to the 5T4-negative HepG2 or Ramos cell lines^[1].
ZV05 (multiple concentrations; 72 h) shows no cytotoxicity against the 5T4-positive cancer cell lines MDA-MB-468, DU 145, BxPC-3, Lovo, as well as the 5T4-negative human cancer cell line HepG2 following 72 h of incubation^[1].
ZV05 (0.139-10 μg/mL; 72 h) does not induce apoptosis in 5T4-positive MDA-MB-468 and DU 145 cancer cell lines even at concentrations up to 10 μg/mL after 72 h of incubation^[1].
ZV05 (0.139-10 μg/mL; 72 h) does not interfere with cell cycle progression or induce G₂/M phase arrest in the 5T4-positive human cancer cell lines MDA-MB-468 and DU 145, even at concentrations up to 10 μg/mL following a 72 h incubation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ZV05 (5 mg/kg; i.v.; single dose) specifically accumulates in 5T4-positive MDA-MB-468 tumor tissue in vivo^[1].
ZV05 (5 mg/kg; i.v.; single dose) does not specifically accumulate in 5T4-negative Romas tumor tissue in vivo^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

7162  [NCBI]

Q13641

TPBG

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Shi B, et al. Antitumor activity of a 5T4 targeting antibody drug conjugate with a novel payload derived from MMAF via C-Lock linker. Cancer Med. 2019 Apr;8(4):1793-1805.  [Content Brief]

  [2]. Li Z, et al. Development of anti-5T4 antibody-drug conjugates, ZV05-ADCs for targeted cancer therapy in different type of cancers[J]. Cancer Research, 2016, 76(14_Supplement): 1214-1214.